{
    "nctId": "NCT02447328",
    "briefTitle": "A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex\u00ae ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer",
    "officialTitle": "A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex\u00ae ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Locally Advanced or, Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "NA",
    "primaryPurpose": "OTHER",
    "enrollmentCount": 83,
    "primaryOutcomeMeasure": "Safety(Percentage of Participants With Adverse Events and/or Adverse Drug Reactions)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Post menopausal status women\n* Outpatient or inpatient with locally advanced or metastatic breast cancer who have failed with prior anti-estrogen therapy.\n* Estrogen receptor positive\n* Radiographic progression of disease after the prior therapy\n* Patients who agree to participate in this study and sign the informed consent\n\nExclusion Criteria:\n\n* Patients who are treated with fulvestrant\n* Patients who are being treated with the other antitumor agents\n* Pregnancy or lactating women\n* History of hypersensitivity to any of included ingredients (eg. Castor oil)\n* Patients who are considered not fit for the study by investigators\n* Patients who have severe dysfunction of liver or kidney",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}